Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044148 · ClinicalTrials.gov registry record · Phase 2
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00044148 is a Phase 2 study that has completed, run by Chromaderm.
The verdict
NCT00044148, a Phase 2 study, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
Interventions
- DRUG LY333531
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-07-16 |
| Est. Completion | 2004-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044148
The ClinicalTrials.gov registry entry for NCT00044148 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Chromaderm, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY333531 is the first listed.
NCT00044148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044148 about?
NCT00044148 is a clinical study titled "The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes". The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
What is the current status of trial NCT00044148?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-07-16. Estimated completion is 2004-04-28.
What interventions are being tested in trial NCT00044148?
The interventions under investigation include: LY333531 (DRUG).
Who is sponsoring clinical trial NCT00044148?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.